Festival of Biologics

Join our partner #GlobalBiosimilarsWeek on November 11-15, 2024! This year, they will focus on Advancing Access to Biosimilars, helping more people live healthier lives worldwide. Find out more now at https://lnkd.in/dVJaEPDY

#LISAOnTour: Throwback to the Festival of Biologics in Basel! ⏪ From October 15–17, Anna Weihs represented our Life Science team at the Festival of Biologics in Basel. This conference offered valuable insights into the field of biologics development, spanning the entire lifecycle - from discovery and development through to manufacturing, clinical trials, and commercialization. With over 3,000 attendees, discussions among leaders from pharma, biotech, and academia underscored the importance of sustainable and affordable access to #biosimilars globally. We were especially pleased to see two Austrian startups, bespark*bio and RNAnalytics, making impactful contributions on this international stage - both of which are supported by Austria Wirtschaftsservice’s Deep Tech funding! 🚀

Recap a wonderful week at Festival of Biologics in Basel, Switzerland! We celebrated the launch of our own Super Refined™ Poloxomer 188, optimised specifically for mammalian cell culture with tightly controlled impurity profiles and molecular weight, ensuring optimal cell culture performance and batch-to-batch consistency. Next week we are on the road again, attending World Vaccine Congress Europe. Visit us at 110 to meet our team of scientists and experts and learn how we are expanding our offer and unlocking sustainable ingredients for vaccines. See you there! #festivalofbiologics #crodapharma

Early Bird Pricing Won’t Last Forever! 🕒 Early Bird registration for the Festival of Biologics is ending today, and this is your last opportunity to register at a discounted rate. Join us for an unforgettable event at the best possible price. Register now before it’s too late 👉 https://lnkd.in/ebr-7PTm #festivalofbiologics #festofbiologicsUSA

Ein großes Dankeschön an alle Beteiligten des Festival of Biologics. Die thematische Bandbreite sowie die Qualität der Vorträge waren beeindruckend. Auch die Vielfalt der ausstellenden Unternehmen und die vielen anregenden Gespräche haben das Event besonders gemacht. --- A big thank you to everyone involved in the Festival of Biologics. The thematic range and the quality of the presentations were impressive. The diversity of the exhibiting companies and the many stimulating discussions also made the event special. #FestivalOfBiologics #Networking #Pharma #Basel #GMP

Reflecting on a great Festival of Biologics 2024 in Basel! It was a fantastic event filled with thought-provoking panels, dynamic discussions, and the perfect opportunity to reconnect with familiar faces and to build new relationships.   It was a pleasure to join the panel discussion in finance & investment for Start-ups with Dominik Escher, Managing Partner representing Pureos Bioventures and the very insightful keynote panel discussion “Accelerating ADC and Bioconjugate Development" with Dragan Grabulovski (Araris Biotech AG) and Jack Elands (Adcytherix) representing two Pureos Portfolio companies. Looking forward to the Festival of Biologics 2025!

It’s Been a Week Since the Festival of Biologics—What an Experience! 🙌 We’re still buzzing from the incredible energy, groundbreaking insights, and meaningful connections throughout #festivalofbiologics. With over 3000 registered attendees, this year’s event exceeded all expectations. A huge thank you to all the speakers, exhibitors, and attendees who made it a success! What were your favourite highlights? Let us know in the comments below 👇

Early Bird Pricing Ends Soon! ⏰ Our early bird is ending this Friday. Don't miss out on the chance to save over $1000 on conference passes. Why not invite your colleagues and enjoy up to 50% discount? Get your group tickets now! Lock in your savings and be part of an amazing event 👉 https://lnkd.in/ebr-7PTm We can’t wait to see you there! #festivalofbiologics #festofbiologicsUSA

🌟 Festival of Biologics: The future of Biologics and the Biosimilars market; where is it all going? 🌟 Last week, I had the chance to attend the 3-day Festival of Biologics in Basel where a lot of exciting discussions took place. Here are my personal takeaways: 💡 Biologics & Biosimilars: Biologics have evolved in waves: therapeutic proteins, monoclonal antibodies, and therapeutic antibodies. We are now in the third wave, which includes gene therapies and CAR-T, offering curative potential but facing high costs and regulatory challenges. Biosimilars are near-identical copies of biologic drugs that offer a more affordable alternative once the original biologic's patent expires, helping improve access to treatment for patients and healthcare systems. ⚖️ Regulatory challenges: The current regulatory landscape for biologics is both complex and evolving. Under the Biologics Price Competition and Innovation Act (BPCIA) in the U.S., reference biologics are protected by a 12-year exclusivity period, allowing innovators to recoup their investment (as developing a biologic can cost more than $3 billion). However, this exclusivity delays biosimilar competition, limiting potential cost savings for patients and governments seeking to provide innovative therapeutics to their population. Despite efforts to reduce regulatory burdens, biosimilars still face high costs due to similar clinical requirements (toxicity, PK studies, etc.). This narrows the price gap between biosimilars and reference biologics drugs, making it harder for biosimilars to penetrate certain markets and for governments to afford them. 🚀 Biosimilar approvals & market growth: As of October 2024, the FDA approved 62 biosimilars, with 42 launched in the U.S, covering major therapeutic areas like oncology, immunology, endocrinology, and ophthalmology. In addition, the market concentration of biologics production remains an issue: the U.S. and Europe account for 36% and 25 % of global production respectively, leaving other regions with limited access to cost-saving therapeutics and alternatives. ⚙️ Innovation in manufacturing: To make biologics more accessible, innovation in manufacturing is key. Leveraging mRNA-based therapies, using the human body as a natural bioreactor to produce biologics in-situ, could reduce production costs and regulatory delays. 💬 Strategic insights from the speakers: As the biologics industry evolves, pushing for globally harmonized regulatory frameworks and collaboration between all stakeholders (innovators, regulators, and governments) that support both innovation and affordability is essential to making groundbreaking therapies accessible. A huge thank you to the organizers, Terrapinn, for the invitation and the opportunity to exchange ideas with industry leaders and gain valuable insights ! #biologics #biosimilars #regulatorychallenges #healthcareinnovation #genetherapies #therapies #futureofhealthcare #festivalofbiologics #pricingstrategies

We had an inspiring and insightful time at the Festival of Biologics in Basel, where we gave keynote talks, presented posters, and led panel and roundtable discussions joined by top minds from pharma, biotech, and research. It was a great chance to dive into cutting-edge topics in biotherapeutic R&D.   One story from the AI panel discussion really stuck: A customer shared how an FTE spend three years curating data for developability prediction—only to throw out 50% of it due to inaccuracy. Once they had Genedata, they achieved accurate predictions on 10-year-old data in just six months. https://lnkd.in/djzyGb3H   We are looking forward to another great event next year.   #DigitalizingBiopharma #Innovation #FOB #Recap